Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Immunological derangement in hypocellular myelodysplastic syndromes

    ... , anti-thymocyte globulin and/or cyclosporine, or alemtuzumab . Here we review all these immune mechanisms as well as the ...

    Research Article last updated 05/22/2014 - 9:53am.

  2. A Rare Case of Aplastic Anemia Later in Life Doesn’t Stop Al Meyer

    ... stem cell transplant . So that’s when I was put on alemtuzumab (Campath®), which I had no response to.  So in late 2013, ...

    Patient Chronicle last updated 07/12/2017 - 1:52pm.

  3. Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

    ... be given on study is fludarabine , melphalan, and alemtuzumab . These drugs are designed to stop the growth of cancer cells, ... mg/m2 by vein on Day -2. Other Name: Alkeran Drug: Alemtuzumab 50 mg by vein on Day -1. Other Names: ...

    Clinical Trial last updated 06/06/2016 - 12:41pm.

  4. Drugs

    ... Name Brand Name alemtuzumab C ampath ...

    Page last updated 03/02/2016 - 9:11am.

  5. Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

    ... antibodies. The main transplant backbone will remain as alemtuzumab , low dose total body irradiation of 300 cGy, and sirolimus; the ... Intervention:  Drug: Alemtuzumab Immunosuppressant Drug: Sirolimus ...

    Clinical Trial last updated 04/28/2016 - 9:09am.

  6. Myelodysplastic Syndromes and autoimmune disorders: Cause or consequence?

    ... (ImiDs), antithymocyte globulin (ATG), and alemtuzumab ) due to the autoimmune component. ...

    Research Review last updated 05/02/2016 - 9:18am.

  7. Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide

    ... of the following: Cytotoxic chemotherapy , alemtuzumab , or an adequate course of 5- azacitidine or ...

    Clinical Trial last updated 05/02/2016 - 2:38pm.

  8. Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

    ... Planned use of anti-thymocyte globulin (ATG) or alemtuzumab in conditioning regimen. Planned post-transplant therapy, ...

    Clinical Trial last updated 06/06/2016 - 1:59pm.

  9. Bogdan Dumitriu, MD

    ... Granular Lymphocytes Lymph proliferative Disorders with Alemtuzumab . ...

    Page last updated 04/18/2012 - 1:49pm.

  10. Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS

    ... Associated Drug(s):  Alemtuzumab Fludarabine ... Drug: Reduced-Intensity Conditioning Regimen Campath (alemtuzumab) - drug class: monoclonal antibody Droxia (hydroxyurea) - drug ...

    Clinical Trial last updated 05/03/2016 - 10:36am.